16.1 Glycogen Metabolism

Glycogen metabolism governs how your body stores glucose and retrieves it on demand. Two opposing processes make this work: glycogenesis (building glycogen) and glycogenolysis (breaking it down). Together, they maintain blood sugar levels and supply quick energy during exercise or fasting.

These pathways sit at the center of carbohydrate metabolism. Grasping how they're regulated, and what happens when they malfunction, gives you a framework for understanding hormonal signaling, energy balance, and several clinically important diseases.

Glycogen Synthesis and Structure

Glycogen Structure and Function

Glycogen is the primary storage form of glucose in animals. It's a large, branched polymer of glucose residues with two types of linkages:

• α-1,4 glycosidic bonds connect glucose units in long linear chains
• α-1,6 glycosidic bonds create branch points roughly every 8–12 residues

This branching produces a tree-like structure with many non-reducing ends. That matters because enzymes that build or break down glycogen work at non-reducing ends, so more branches mean faster synthesis and degradation.

Glycogen is stored mainly in two tissues:

• Liver (up to ~100 g): releases glucose into the blood to maintain systemic glucose levels
• Skeletal muscle (up to ~400 g): uses glucose locally for contraction; muscle lacks the enzyme to export free glucose

Glycogenesis Process

Glycogenesis is the synthesis of glycogen from glucose. It ramps up when blood glucose is high, typically after a meal. Here's how it works, step by step:

1. Glucose → Glucose-6-phosphate (catalyzed by hexokinase or glucokinase)
2. Glucose-6-phosphate → Glucose-1-phosphate (catalyzed by phosphoglucomutase)
3. Glucose-1-phosphate + UTP → UDP-glucose + PPi (catalyzed by UDP-glucose pyrophosphorylase). Pyrophosphate (PPi) is immediately hydrolyzed, driving the reaction forward.
4. UDP-glucose donates its glucose to the non-reducing end of a growing glycogen chain, forming a new α-1,4 bond (catalyzed by glycogen synthase)
5. Branching enzyme transfers a block of ~7 glucose residues from the end of a chain and reattaches it via an α-1,6 bond, creating a new branch point

Note that glycogen synthase cannot start a chain from scratch. It requires a primer protein called glycogenin, which self-glucosylates to create a short initial chain that glycogen synthase can then extend.

Enzymes and Molecules Involved in Glycogen Synthesis

• Glycogen synthase is the key regulatory enzyme. It catalyzes α-1,4 bond formation and is active in its dephosphorylated form (glycogen synthase a). Phosphorylation inactivates it (glycogen synthase b). Glucose-6-phosphate acts as an allosteric activator.
• UDP-glucose is the "activated" glucose donor. It's formed from glucose-1-phosphate and UTP by UDP-glucose pyrophosphorylase. The energy cost of activation is one UTP per glucose added.
• Branching enzyme (amylo-α-1,4→α-1,6-transglucosidase) transfers segments of 6–8 glucose units to create α-1,6 branch points. Branching increases glycogen's solubility and creates more non-reducing ends for rapid mobilization.

Glycogen Breakdown

Glycogenolysis Process

Glycogenolysis is the breakdown of glycogen to release glucose units. It's triggered when blood glucose drops (between meals, during fasting, or during exercise). The process works inward from the many non-reducing ends of the glycogen tree, which allows rapid mobilization.

The primary product is glucose-1-phosphate, not free glucose. What happens next depends on the tissue:

• In muscle, glucose-1-phosphate is converted to glucose-6-phosphate and fed into glycolysis for ATP production
• In liver, glucose-6-phosphate is dephosphorylated by glucose-6-phosphatase to yield free glucose, which is exported into the blood

Muscle cells lack glucose-6-phosphatase, so muscle glycogen fuels only local energy needs.

Key Enzymes in Glycogen Breakdown

Glycogen phosphorylase catalyzes the main degradative step:

• Cleaves α-1,4 bonds by adding inorganic phosphate ($P_i$) across the bond (phosphorolysis, not hydrolysis)
• Releases glucose-1-phosphate from non-reducing ends
• Stops four residues away from a branch point; it cannot cleave near α-1,6 linkages

Debranching enzyme handles the branch points and has two distinct catalytic activities:

1. Transferase activity: moves a block of three glucose residues from the branch stub to a nearby non-reducing end (α-1,4 linkage)
2. α-1,6-glucosidase activity: hydrolyzes the single remaining α-1,6-linked glucose, releasing it as free glucose (not glucose-1-phosphate)

So for every ~8–12 glucose residues released as glucose-1-phosphate by phosphorylase, about one is released as free glucose by the debranching enzyme.

Products and Regulation of Glycogenolysis

Glucose-1-phosphate is the main product. Phosphoglucomutase converts it to glucose-6-phosphate, which then enters glycolysis (muscle) or is dephosphorylated to free glucose for export (liver).

Regulation occurs at multiple levels:

Hormonal control (covalent modification):

• Glucagon (from the pancreas, acts on liver) and epinephrine (acts on liver and muscle) activate a signaling cascade that phosphorylates glycogen phosphorylase, switching it to its active a form
• Insulin opposes this by activating phosphatases that dephosphorylate (and inactivate) glycogen phosphorylase

Allosteric control:

• In muscle, AMP activates phosphorylase b (signaling low energy), while ATP and glucose-6-phosphate inhibit it (signaling adequate energy)
• In liver, glucose itself acts as an allosteric inhibitor of phosphorylase a, providing direct feedback when blood glucose is restored
• Calcium ions (released during muscle contraction) activate phosphorylase kinase, linking glycogenolysis to muscle activity

Disorders of Glycogen Metabolism

Types of Glycogen Storage Diseases

Glycogen storage diseases (GSDs) are inherited disorders caused by defects in enzymes of glycogen metabolism. There are over a dozen types, but three are most commonly tested:

• Type I (von Gierke's disease): deficiency of glucose-6-phosphatase in the liver. The liver can break down glycogen but cannot release free glucose into the blood. This leads to severe fasting hypoglycemia, glycogen and fat accumulation in the liver and kidneys, lactic acidosis (because glucose-6-phosphate is shunted into glycolysis and then to lactate), and growth retardation.
• Type II (Pompe's disease): deficiency of lysosomal acid α-1,4-glucosidase (acid maltase). Glycogen that enters lysosomes cannot be degraded, so it accumulates in lysosomes across many tissues. The result is progressive muscle weakness and cardiomyopathy. This is the only GSD that is a lysosomal storage disease.
• Type III (Cori's disease): deficiency of the debranching enzyme. Glycogen phosphorylase works normally but stalls at branch points, so abnormally structured glycogen with short outer branches accumulates. Symptoms include hepatomegaly (enlarged liver), muscle weakness, and fasting hypoglycemia, though typically milder than Type I.

Clinical Manifestations and Diagnosis

Symptoms vary by type, but common features across many GSDs include:

• Hypoglycemia (especially fasting hypoglycemia in Types I and III)
• Hepatomegaly from glycogen accumulation in the liver
• Muscle weakness or exercise intolerance

Diagnosis typically involves a combination of approaches:

1. Clinical presentation and family history (GSDs are autosomal recessive)
2. Biochemical tests: blood glucose, lactate, uric acid, liver enzymes
3. Enzyme activity assays on tissue samples to identify the specific deficiency
4. Liver or muscle biopsy to assess glycogen content and structure
5. Genetic testing to confirm the mutation and enable family screening

Management and Treatment Approaches

Treatment focuses on symptom management and preventing complications, since most GSDs cannot be cured:

• Dietary management is central for most types. Frequent small meals with complex carbohydrates help maintain blood glucose. For Type I, uncooked cornstarch supplements provide slow-release glucose that prevents overnight hypoglycemia.
• Enzyme replacement therapy (ERT) is available for Pompe's disease (Type II). Recombinant acid α-glucosidase is administered intravenously and has significantly improved outcomes.
• Liver transplantation may be considered in severe cases with liver failure or poor metabolic control.
• Regular monitoring of blood glucose, liver function, growth parameters, and organ-specific complications is essential for long-term management.
• Physical therapy helps maintain muscle strength and function, particularly in types with myopathy.
• Genetic counseling is recommended for affected families, since GSDs follow autosomal recessive inheritance patterns.